loader2
Partner With Us NRI

Alkem Laboratories Ltd share Price Today

Company details

5,086.00
5,086.00
3,307.20
5,578.80
6M Return 6.06%
1Y Return 51.93%
Mkt Cap.(Cr) 60,810.76
Volume 22
Div Yield 0.79%
OI
-
OI Chg %
-
Volume 22

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Alkem Laboratories announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Total Revenue from Operations were Rs 29,358 million, YoY growth of 1.1%.
  • India sales were Rs 19,724 million, YoY de-growth of 1.9%.
  • International sales were Rs 9,096 million, YoY growth of 6.1%.
  • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 4,020 million, resulting in EBITDA margin of 13.7% vs. 12.2% in Q4FY23. EBITDA increased by 13.8% YoY.
  • R&D expenses for the quarter was Rs 1,757 million, or 6.0% of total revenue from operations compared to Rs 1,472 million in Q4FY23 at 5.1% of total revenue from operations
  • Profit before tax (PBT) before exceptional item was Rs 3,799 million, a growth of 20.7% compared to Rs 3,146 million in Q4FY23.
  • Net Profit (after Minority Interest) was Rs 2,936 million, YoY growth of 313.6%.
  • PAT for Q4FY23 was impacted on account of derecognition of deferred tax of Rs 1,197 million.
  • Adjusted for the above item, PAT growth for Q4FY24 would have been 54%.
  • As per IQVIA data, for Q4FY24, the company registered a growth of 1.4% YoY vs. the Indian Pharmaceutical Market (IPM) which grew by 5.7%

FY24 Financial Highlights:

  • Total Revenue from Operations was Rs 1,26,676 million, YoY growth of 9.2%.
  • India sales were Rs 84,337 million, YoY growth of 5.4%.
  • International sales were Rs 40,024 million, YoY growth of 16.4%.
  • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 22,455 million, resulting in EBITDA margin of 17.7% vs. 13.9% in FY23. EBITDA increased by 39.5% YoY.
  • R&D expenses for FY24 was Rs 5,229 million, or 4.1% of total revenue from operations compared to Rs 5,394 million in FY23 at 4.7% of total revenue from operations
  • Profit before tax (PBT) before exceptional item was Rs 21,446 million, a growth of 52.3% compared to Rs 14,078 million in FY23.
  • Net Profit (after Minority Interest) was Rs 17,958 million, YoY growth of 82.5%.
  • PAT for FY23 was impacted on account of derecognition of deferred tax of Rs 1,197 million. Adjusted for the above item, PAT growth for FY24 would have been 62.7%.
  • As per IQVIA data, for FY24, the company registered a growth of 6.2% YoY, vs. the Indian Pharmaceutical Market (IPM) which grew by 7.6%
  • We are pleased to share that the international business has crossed revenue of Rs 40 billion in FY24.

Commenting on the FY24 results, Vikas Gupta, CEO, Alkem said "Our focus has been to improve EBIDTA margin during the year, on the back of benefits through various cost -control initiatives being implemented along with favourable API prices. Continuing our trend of improved performance, Q4FY24 builds on the momentum gained from previous quarters with significant gross margin enhancements backed by lower raw material cost and lower intensity of price erosion in US. Lower Opex across our manufacturing facilities and R&D also aided EBDITA margin. Our Biosimilars and international business has delivered strong growth across geographies. Our anti-diabetic portfolio continues to outperform the market. We are committed to carrying forward the momentum of better operational performance, building on our recent success."

Result PDF

View Other Company Results

Alkem Laboratories Ltd shares SWOT Analysis

Strengths (8)

  • Company with high TTM EPS Growth
  • Strong Annual EPS Growth
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Weakness (4)

  • MFs decreased their shareholding last quarter
  • Declining Revenue every quarter for the past 2 quarters
  • Declining profits every quarter for the past 2 quarters

Opportunity (0)

Data not found

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 5,114.5
R2 5,150.9
R3 5,181.2
Pivot

5,084.28

S1 5,047.9
S2 5,017.6
S3 4,981.2
EMA SMA
5,044.7
5,040.2
4,951.9
4,663.4
5,137.6
5,001.3
5,040.8
4,617.8
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SOCIETE GENERALE Block Purchase 2024-04-26 4867.65 103803 BSE
MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUND Block Sell 2024-04-26 4867.65 103803 BSE
SOCIETE GENERALE Block Purchase 2024-01-25 4999.6 308994 BSE
Name Category Shares
Sarandhar Singh* (please refer notes) PROMOTER 20.66%
Basudeo Narain Singh PROMOTER 7.27%
Mritunjay Kumar Singh PROMOTER 6.42%
Madhurima Singh$ (please refer notes) PROMOTER 5.39%
Madhurima Singh@ (please refer notes) PROMOTER 2.59%
Jayanti Sinha PROMOTER 2.46%
Seema Singh PROMOTER 2.46%
Archana Singh PROMOTER 2%
Aniruddha Singh& (please refer notes) PROMOTER 1.01%
Divya Singh& (please refer notes) PROMOTER 1.01%
Meghna Singh PROMOTER 1.01%
Shrey Shree Anant Singh PROMOTER 1%
Madhurima Singh& (please refer notes) PROMOTER 0.79%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Alkem Laboratories Ltd Stocks COMPARISON

Financials( in Cr) Alkem Laboratories Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 5,086.00 1,514.60 1,550.00 4,501.30 1,105.00
% Change 0.16 0.51 0.59 1.10 0.73
Mcap Cr 60,810.76 363,403.28 125,141.89 119,495.56 111,188.86
Revenue TTM Cr 11,599.26 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 1,006.81 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 32.10 36.10 29.21 73.81 28.64
1 Year Return 51.93 53.70 61.47 30.91 116.67
ROCE 12.48 16.79 14.76 19.30 16.25
ROE 11.39 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 9,045.29 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 34,884.91 -9,332.45
LAST 3M 106,892.87 -46,178.73
LAST 6M 180,013.62 -16,713.35
LAST 12M 285,796.32 100,710.28
Alkem Laboratories Limited - Updates

Jun 10, 2024 l NSE Announcement

Alkem Laboratories Limited - Acquisition

Jun 07, 2024 l NSE Announcement

Alkem Laboratories to invest Rs 30 cr in HaystackAnalytics

Jun 06, 2024 l BSE Announcement

Date Action Type Ratio
Feb 16, 2024 Dividend 1750
Aug 10, 2023 Dividend 500
Feb 17, 2023 Dividend 750

Alkem Laboratories Ltd Information

Stock PE (TTM)
32.1
Promoter Holding
56.74%
Book Value
862.465
ROCE
12.48%
ROE
11.39%
Description
  • Alkem Laboratories Ltd. is a multinational pharmaceutical company based in India. It manufactures and markets pharmaceutical formulations, generics, and nutraceuticals. It was incorporated in 1973, with its headquarters in Mumbai. In the June 2022 quarter, Alkem Laboratories Ltd. recorded a total income of Rs 2,627.79 crore, up 4.93% against Rs 2,504.38 crore in the March 2022 quarter. The company’s market capitalisation on 10 October 2022 stood at Rs 37,957 crore.

    The company is listed on the Bombay Stock Exchange with the code 539523, and on the National Stock Exchange with the code ALKEM.

    Alkem Laboratories Ltd. is a leading player in the branded and generic drugs space. It has a significant brand share in the cardiovascular, anti-diabetic, central nervous system, anti-osteoporosis, immunosuppressants, anti-malarial, and nutraceutical segments. The company leads the Indian market in the pain management and anti-infective segments. Alkem was awarded the 31st rank in India’s Best Companies to Work for in 2022 by the Great Place to Work Institute.

    The company’s shareholding pattern as of 30 June 2022 represented a 57.14% promoter stake, 5.67% foreign institutional investor stake, 14.1% domestic institutional investor stake, and 23.09% public stake. During the June 2022 quarter, promoter holdings increased from 57.13% to 57.14%, mutual fund holdings increased from 7.52% to 7.85%, and FII holdings also increased from 5.41% to 5.67%.

    The company’s board of directors comprise Mr Basudeo N Singh, Mr Sandeep Singh, Mr Mritunjay Singh, Mr Sarvesh Singh, Mr Srinivas Singh, Mr Arun Purwar, Mr Narendra K Aneja, Dr Dheeraj Sharma, Ms Sangeeta K Singh, and Ms Sudha Ravi. The auditors are BSR & Co. LLP. On 30 June 2022, the company recorded a total of 11.96 crore shares outstanding.

    On 10 October 2022, the company’s BSE share price closed at Rs 3,172.80. Alkem Laboratories Ltd.’s NSE share price closed at Rs 3,174.65. The company’s 52-week high share price was Rs 3,990, while the 52-week low for the company’s share price was Rs 2,828. Alkem Laboratories Ltd.’s share gave investors a one-year return of -18.79%.

    The company’s peers in the pharmaceutical sector include Sun Pharmaceutical Industries Ltd., Dr Reddys Laboratories Ltd., Divis Laboratories Ltd., and Cipla Ltd.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose

Registered Address

Alkem House SenapatiBapat Marg, Lower Parel, Mumbai, Maharashtra, 400013

Tel : 91-22-39829999
Email : investors:alkem.com ; contact:alkem.com
Website : http://www.alkemlabs.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 539523
NSE Code : ALKEM
Book Closure Date (Month) :
BSE Group : A
ISIN : INE540L01014

FAQ’s on Alkem Laboratories Ltd Shares

You can buy Alkem Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Alkem Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 13, 2024 09:07 AM the closing price of Alkem Laboratories Ltd was Rs.5,086.00.

The latest PE ratio of Alkem Laboratories Ltd as of Jun 13, 2024 09:07 AM is 32.10

The latest PB ratio of Alkem Laboratories Ltd as of Jun 13, 2024 09:07 AM is 0.17

The 52-week high of Alkem Laboratories Ltd share price is Rs. 5,578.80 while the 52-week low is Rs. 3,307.20

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 13, 2024 09:07 AM, the market cap of Alkem Laboratories Ltd stood at Rs. 60,810.76.

Download App

Download Our App

Play Store App Store
market app